Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Pharma Stocks
Pharma Stocks collects four articles on big pharma movers, from Novo Nordisk to Merck, highlighting value, growth angles, and dividend potential to help smarter investing.
48 articles
Bearishness Around Pfizer Gilead Sparks Opportunity
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
Does Vertex's Acquisition Crinetics Make Stock a Buy?
If Vertex pursues Crinetics, what would it mean for the stock? This article breaks down potential value, risks, and t...
Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Lilly Novo Nordisk Fine: Two Stocks Riding GLP-1 Boom
The GLP-1 wave has traders buzzing. While Lilly and Novo Nordisk hold steady as reliable bets, smart portfolios tap i...
Lilly Teva: Which Pharmaceutical Stock Shines in 2026?
As 2026 unfolds, investors face a clear choice between Lilly's growth engine in big markets and Teva's value-forward ...
Johnson Johnson Walking Away Could Boost Long-Term Value
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
AbbVie Stock Hits 52-Week High: Is It Priced Right
AbbVie stock recently surged to a fresh 52-week high, impressing bulls while raising questions about value. This guid...
Better Obesity Drug Race: Novo Nordisk vs Lilly 2026
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Underrated Weight Loss Stocks: Two Buys for Long-Term Hold
The weight loss therapy wave has fireworks at the giants, but smart investors look for underrated weight loss stocks ...
Teva's Biosimilar Boom Just Beginnings: Is It Time to Buy?
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...